A promising experimental drug is one more sign of the impending disruption the booming Chinese biotech industry could bring ...

An obesity drug from Hengrui Pharma and Kailera Therapeutics succeeded in a late-stage trial in China, while Anne Wojcicki's ...

Eli Lilly & Co. Inc.'s stock (LLY) rose 2.3% Wednesday, after the company said its Zepbound weight-loss drug was more effective than rival Novo Nordisk's Wegovy in a head-to-head study.

Seemingly bad news can sometimes be really good news. I think a recent study for Eli Lilly's (LLY-2.28%) rival to Novo Nordisk's massively successful Ozempic and Wegovy provides a great case in point.

Eli Lilly said its recently approved weight loss treatment Zepbound is now available at pharmacies across the U.S. The drug serves as an alternative to rival obesity drugs such as Wegovy that are ...

Eli Lilly said it has started selling single-dose vials of its uber-popular weight-loss drug Zepbound as demand soars – and the smaller doses cost 50% less than rival drugs.

Eli Lilly said its weight loss drug Zepbound led to 47% greater weight reduction than rival medicine Wegovy, made by Novo Nordisk, in a head-to-head randomized controlled trial.

Eli Lilly said its obesity drug Zepbound led to more weight loss than its main rival, Novo Nordisk's Wegovy, in the first head-to-head clinical trial on the two weekly injections. The findings ...

Zepbound will list at $1,059.87 a month, according to Lilly. That compares with a list of $1,349 per-package for Novo Nordisk's wildly popular weight-loss drug Wegovy.

Eli Lilly & Co. Inc.’s stock LLY rose 1.5% early Wednesday, after the company said its Zepbound weight-loss drug was more effective than rival Novo Nordisk’s Wegovy in a head-to-head study ...

The Food and Drug Administration on Friday approved Eli Lilly's blockbuster weight loss drug Zepbound for treating patients with the most common sleep-related breathing disorder, expanding its use ...